Friday, 16 October 2026European Markets

BARBARA BUI Stock Is 27% Down So Far On Tuesday

Loading stream...

barbara bui (cac 40: bui.pa), a women's ready-to-wear and accessories manufacturer, experienced a dramatic 27.72% drop to eur7.30 at 14:52 est tuesday - marking five consecutive days of losses. these figures may reflect a more bearish trading trend prevalent across the cac 40 index, which also underwent a 0.86% decline to eur7,433.64 following three profitable sessions.

roots of barbara bui's decline

the decline in barbara bui's share value can be traced back to its prior close of eur10.10, which stood 3.81% below its 52-week high of eur10.50. in addition, the shares of barbara bui are now significantly below both their 50-day moving average of eur9.24 and 200-day moving average of eur7.86; as reported on by business wire on 6/18/16.

financial performance of barbara bui

the paris-based company, founded in 1983, has seen remarkable earnings per share (eps) growth over the last year, with a trailing twelve month eps of eur1.61. this yields an attractive trailing p/e ratio of 4.53 i.e. investing eur4.53 in each euro of annual earnings. moreover, their return on equity (roe) also stands out at an impressive 61.8%, highlighting high profitability using shareholder funds.

recent trading activities of barbara bui

barbara bui's stock was trading at only 5 shares on friday morning as compared to its average volume of 36 on average in prior trading sessions. this suggests a reduction in trading activity and, potentially, decreased liquidity on the market for this company's shares.

glimmers of hope for barbara bui

some optimism is present, as barbara bui reported a 7.9% year-on-year quarterly revenue growth with trailing twelve month revenue standing at eur10.92m. barbara bui's share value has also witnessed considerable growth since hitting its 52-week low of eur6.30 during its recent plummet.

conclusion

in conclusion, barbara bui's sharp share price decrease seems to mirror broader market bearish trends. however, with its impressive return on equity, positive revenue growth, and impressive past eps performance, there's potential for a rebound in its share value. keeping an eye on its future performance will be necessary to ascertain if it can reverse this recent downward trend.

more news about barbara bui (bui.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com